JP7258778B2 - 感染によるものではない刺激の治療のための点眼剤 - Google Patents
感染によるものではない刺激の治療のための点眼剤 Download PDFInfo
- Publication number
- JP7258778B2 JP7258778B2 JP2019568840A JP2019568840A JP7258778B2 JP 7258778 B2 JP7258778 B2 JP 7258778B2 JP 2019568840 A JP2019568840 A JP 2019568840A JP 2019568840 A JP2019568840 A JP 2019568840A JP 7258778 B2 JP7258778 B2 JP 7258778B2
- Authority
- JP
- Japan
- Prior art keywords
- aqueous solution
- glycerol
- ophthalmic formulation
- carbomer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims description 41
- 230000007794 irritation Effects 0.000 title claims description 34
- 239000003889 eye drop Substances 0.000 title description 18
- 229940012356 eye drops Drugs 0.000 title description 17
- 208000015181 infectious disease Diseases 0.000 title description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 171
- 239000000203 mixture Substances 0.000 claims description 76
- 239000007864 aqueous solution Substances 0.000 claims description 57
- 238000009472 formulation Methods 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 47
- 210000002919 epithelial cell Anatomy 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 20
- 238000010186 staining Methods 0.000 claims description 19
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 16
- 229920002125 Sokalan® Polymers 0.000 claims description 16
- 229960001631 carbomer Drugs 0.000 claims description 16
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 13
- KZMRYBLIGYQPPP-UHFFFAOYSA-M 3-[[4-[(2-chlorophenyl)-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]-n-ethylanilino]methyl]benzenesulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)Cl)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 KZMRYBLIGYQPPP-UHFFFAOYSA-M 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- 230000004489 tear production Effects 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000000243 solution Substances 0.000 description 25
- 230000000638 stimulation Effects 0.000 description 16
- 230000005779 cell damage Effects 0.000 description 9
- 208000037887 cell injury Diseases 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 5
- 208000023715 Ocular surface disease Diseases 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 229940014041 hyaluronate Drugs 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 206010056476 Corneal irritation Diseases 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 102000003940 Occludin Human genes 0.000 description 2
- 108090000304 Occludin Proteins 0.000 description 2
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000012148 non-surgical treatment Methods 0.000 description 2
- 229930187593 rose bengal Natural products 0.000 description 2
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 2
- 229940081623 rose bengal Drugs 0.000 description 2
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- AQQSXKSWTNWXKR-UHFFFAOYSA-N 2-(2-phenylphenanthro[9,10-d]imidazol-3-yl)acetic acid Chemical compound C1(=CC=CC=C1)C1=NC2=C(N1CC(=O)O)C1=CC=CC=C1C=1C=CC=CC=12 AQQSXKSWTNWXKR-UHFFFAOYSA-N 0.000 description 1
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101001067833 Homo sapiens Peptidyl-prolyl cis-trans isomerase A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467139P | 2017-03-05 | 2017-03-05 | |
| US62/467,139 | 2017-03-05 | ||
| PCT/IL2018/050184 WO2018163151A1 (en) | 2017-03-05 | 2018-02-19 | Eye drops for treatment of irritation not due to infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509092A JP2020509092A (ja) | 2020-03-26 |
| JP2020509092A5 JP2020509092A5 (enExample) | 2021-04-01 |
| JP7258778B2 true JP7258778B2 (ja) | 2023-04-17 |
Family
ID=61656085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568840A Active JP7258778B2 (ja) | 2017-03-05 | 2018-02-19 | 感染によるものではない刺激の治療のための点眼剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11033513B2 (enExample) |
| EP (2) | EP3592339B1 (enExample) |
| JP (1) | JP7258778B2 (enExample) |
| KR (1) | KR102652879B1 (enExample) |
| CN (1) | CN110891555B (enExample) |
| AU (1) | AU2018230262B2 (enExample) |
| BR (1) | BR112019018367A2 (enExample) |
| CA (1) | CA3055523C (enExample) |
| ES (1) | ES3036888T3 (enExample) |
| IL (1) | IL269133B2 (enExample) |
| MX (1) | MX388961B (enExample) |
| PL (1) | PL3592339T3 (enExample) |
| RU (1) | RU2019130955A (enExample) |
| WO (1) | WO2018163151A1 (enExample) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013077433A1 (ja) | 2011-11-24 | 2013-05-30 | 東洋精糖株式会社 | 角結膜保護剤または角結膜障害抑制剤 |
| JP2015507010A (ja) | 2012-02-13 | 2015-03-05 | ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼用医薬組成物およびその製造方法と使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| US5895645A (en) * | 1995-01-31 | 1999-04-20 | Bausch & Lomb Incorporated | Opthalmic solution for artificial tears |
| JP3093661B2 (ja) * | 1995-10-12 | 2000-10-03 | 大塚製薬株式会社 | 眼疾患治療剤 |
| AR004214A1 (es) * | 1995-10-12 | 1998-11-04 | Otsuka Pharma Co Ltd | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas |
| IL120005A (en) * | 1997-01-14 | 2000-08-31 | Ramot University Authority Of | Pharmaceutical compositions for the treatment of the eye |
| US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| IL168603A (en) * | 2005-05-16 | 2011-05-31 | Resdevco Res And Dev Co | Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells |
| DE102005055275A1 (de) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
| IL212725A (en) * | 2011-05-05 | 2016-06-30 | Resdevco Res And Dev Co | Glycerol Preparation for Non-surgical Conjunctivochalysis |
-
2018
- 2018-02-19 JP JP2019568840A patent/JP7258778B2/ja active Active
- 2018-02-19 PL PL18711415.2T patent/PL3592339T3/pl unknown
- 2018-02-19 EP EP18711415.2A patent/EP3592339B1/en active Active
- 2018-02-19 KR KR1020197029124A patent/KR102652879B1/ko active Active
- 2018-02-19 CN CN201880029944.8A patent/CN110891555B/zh active Active
- 2018-02-19 BR BR112019018367A patent/BR112019018367A2/pt not_active Application Discontinuation
- 2018-02-19 ES ES18711415T patent/ES3036888T3/es active Active
- 2018-02-19 WO PCT/IL2018/050184 patent/WO2018163151A1/en not_active Ceased
- 2018-02-19 IL IL269133A patent/IL269133B2/en unknown
- 2018-02-19 MX MX2019010471A patent/MX388961B/es unknown
- 2018-02-19 AU AU2018230262A patent/AU2018230262B2/en active Active
- 2018-02-19 RU RU2019130955A patent/RU2019130955A/ru unknown
- 2018-02-19 CA CA3055523A patent/CA3055523C/en active Active
- 2018-02-19 EP EP24173992.9A patent/EP4385565A3/en active Pending
-
2019
- 2019-09-04 US US16/560,084 patent/US11033513B2/en active Active
-
2021
- 2021-03-03 US US17/191,191 patent/US11426361B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013077433A1 (ja) | 2011-11-24 | 2013-05-30 | 東洋精糖株式会社 | 角結膜保護剤または角結膜障害抑制剤 |
| JP2015507010A (ja) | 2012-02-13 | 2015-03-05 | ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼用医薬組成物およびその製造方法と使用方法 |
Non-Patent Citations (5)
| Title |
|---|
| Journal of Ocular Pharmacology and Therapeutics，1998年，Vol.14, No.6，pp.497-504 |
| Ophtalmologie，1996年，Vol.10，pp.24-27 |
| PLOS ONE，2015年，Vol.10, No.7，e0132656 |
| Seminars in Arthritis and Rheumatism，2015年，Vol.45, No.3，pp.321-327 |
| アレルギー，2002年，Vol.52, No.6，pp.518-521 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3055523A1 (en) | 2018-09-13 |
| EP4385565A2 (en) | 2024-06-19 |
| KR20190129065A (ko) | 2019-11-19 |
| EP3592339A1 (en) | 2020-01-15 |
| US20190388361A1 (en) | 2019-12-26 |
| CN110891555A (zh) | 2020-03-17 |
| US11426361B2 (en) | 2022-08-30 |
| KR102652879B1 (ko) | 2024-03-29 |
| AU2018230262B2 (en) | 2024-01-18 |
| CA3055523C (en) | 2024-10-01 |
| EP3592339C0 (en) | 2025-04-30 |
| IL269133B1 (en) | 2024-05-01 |
| MX388961B (es) | 2025-03-20 |
| EP3592339B1 (en) | 2025-04-30 |
| EP4385565A3 (en) | 2024-08-21 |
| US20210186892A1 (en) | 2021-06-24 |
| AU2018230262A1 (en) | 2019-09-26 |
| WO2018163151A1 (en) | 2018-09-13 |
| PL3592339T3 (pl) | 2025-09-01 |
| RU2019130955A3 (enExample) | 2021-06-24 |
| BR112019018367A2 (pt) | 2020-04-07 |
| US11033513B2 (en) | 2021-06-15 |
| RU2019130955A (ru) | 2021-04-07 |
| CN110891555B (zh) | 2023-12-26 |
| JP2020509092A (ja) | 2020-03-26 |
| MX2019010471A (es) | 2020-02-12 |
| IL269133A (en) | 2019-11-28 |
| IL269133B2 (en) | 2024-09-01 |
| ES3036888T3 (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2687275C2 (ru) | Слезозаменитель, содержащий гиалуронат натрия и карбоксиметилцеллюлозу | |
| AU2011282683B2 (en) | Preservative free brimonidine and timolol solutions | |
| TW201322982A (zh) | 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑 | |
| JP2005513106A (ja) | ヘパリンを保有する眼薬剤 | |
| BR112021000724A2 (pt) | Composições e métodos para tratar os olhos | |
| CN114502155A (zh) | 增强抗老视作用的卡巴胆碱-溴莫尼定制剂 | |
| ES2827426T3 (es) | Composición oftálmica para la protección corneal | |
| KR101412776B1 (ko) | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 | |
| TW201815397A (zh) | 眼科用劑、眼科用藥、以及（a）羥丙基甲基纖維素及（b）維生素e類的用途 | |
| JP7258778B2 (ja) | 感染によるものではない刺激の治療のための点眼剤 | |
| CN110913867B (zh) | 热凝胶化人工泪液 | |
| US8912166B2 (en) | Eye drops for treatment of conjunctivochalasis | |
| US20250360185A1 (en) | Compositions comprising pedf-derived short peptides for the treatment of dry eye diseases | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| JP2019514887A (ja) | グリコーゲンとヒアルロン酸またはその塩との相乗的組み合わせを含む眼科用組成物 | |
| WO2021156856A1 (en) | Topical opthalmological composition containing hyaluronate and taurine having non-newtonian rheological properties | |
| WO2023048174A1 (ja) | 角膜疾患治療剤 | |
| JP2024542280A (ja) | アラニル－グルタミンおよびアラニル－グルタミンを含む眼科用組成物の新規な使用 | |
| BR122025000245A2 (pt) | Usos de extratos de plantas do gênero acronychia, e/ou licaria para tratar os olhos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210218 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220317 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221014 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221014 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20221104 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20221108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230314 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230405 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7258778 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |